AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
Latest Information Update: 20 Mar 2023
At a glance
- Drugs Rencofilstat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms AMBITION
- Sponsors Hepion Pharmaceuticals
Most Recent Events
- 16 Mar 2023 According to a Hepion Pharmaceuticals media release, the company participate in American Chemical Society and the Joseph Priestley Society (ACS-JPS) webinar to present a data from this study and AI drug development.
- 16 Mar 2023 According to a Hepion Pharmaceuticals media release, data from this study was used to design ongoing phase 2b ASCEND-NASH trial.
- 08 Nov 2022 Results of multi-omics analysis presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases